Loading clinical trials...
Loading clinical trials...
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis
Collaborators
NCT06798311 · Urinary Incontinence (UI), Lower Urinary Tract Symptoms (LUTS), and more
NCT07489794 · Multiple Sclerosis, Urinary Incontinence (UI)
NCT05362292 · Urinary Incontinence, Urge, Urinary Incontinence, and more
NCT07105150 · Urinary Incontinence
NCT07209397 · Overactive Bladder, Overactive Bladder (OAB), and more
Alabama Research Center
Birmingham, Alabama
Quality of Life Medical & Research
Tucson, Arizona
UCLA - Urology Sciences Research Foundation
Culver City, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions